Shares of Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) gapped up before the market opened on Monday . The stock had previously closed at $33.56, but opened at $33.64. Acadia Pharmaceuticals shares last traded at $34.09, with a volume of 1,324,483 shares traded.

Several analysts recently weighed in on ACAD shares. Piper Jaffray Cos. restated a “positive” rating and set a $44.00 price objective on shares of Acadia Pharmaceuticals in a research report on Thursday, May 19th. Vetr upgraded Acadia Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $41.00 price objective for the company in a research report on Tuesday, August 2nd. Bank of America Corp. downgraded Acadia Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $40.00 price objective for the company. in a research report on Wednesday, June 22nd. They noted that the move was a valuation call. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Acadia Pharmaceuticals in a research report on Monday, August 8th. Finally, Jefferies Group reiterated a “buy” rating on shares of Acadia Pharmaceuticals in a research report on Wednesday, August 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $45.80.

The company’s market capitalization is $3.91 billion. The stock has a 50-day moving average price of $34.43 and a 200 day moving average price of $30.07.

Acadia Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by $0.14. During the same period last year, the firm posted ($0.39) EPS. The company earned $0.97 million during the quarter, compared to analyst estimates of $0.71 million. The firm’s quarterly revenue was up 96900.0% compared to the same quarter last year. Analysts predict that Acadia Pharmaceuticals Inc. will post ($2.15) EPS for the current fiscal year.

In other Acadia Pharmaceuticals news, Director Edmund Harrigan bought 1,000 shares of Acadia Pharmaceuticals stock in a transaction that occurred on Tuesday, August 16th. The stock was acquired at an average cost of $32.97 per share, for a total transaction of $32,970.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $32,970. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Glenn Baity sold 4,057 shares of the business’s stock in a transaction dated Monday, July 11th. The stock was sold at an average price of $35.00, for a total value of $141,995.00. Following the transaction, the executive vice president now owns 66,978 shares of the company’s stock, valued at $2,344,230. The disclosure for this sale can be found here.

A number of institutional investors have bought and sold shares of the company. New York State Common Retirement Fund boosted its position in Acadia Pharmaceuticals by 13.6% in the fourth quarter. New York State Common Retirement Fund now owns 95,020 shares of the biopharmaceutical company’s stock valued at $3,387,000 after buying an additional 11,400 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Acadia Pharmaceuticals by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 150,666 shares of the biopharmaceutical company’s stock valued at $5,372,000 after buying an additional 1,739 shares during the last quarter. Morgan Stanley boosted its position in Acadia Pharmaceuticals by 9.3% in the fourth quarter. Morgan Stanley now owns 321,183 shares of the biopharmaceutical company’s stock valued at $11,449,000 after buying an additional 27,260 shares during the last quarter. Finally, Westfield Capital Management Co. LP acquired a new position in Acadia Pharmaceuticals during the fourth quarter valued at approximately $52,744,000.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.